# Syndax Pharmaceuticals (SNDX): Analyst Consensus Signals 142.72% Potential Upside

- Link: https://www.directorstalkinterviews.com/syndax-pharmaceuticals-sndx-analyst-consensus-signals-142-72-potential-upside/4121216867
- Published: 2025-09-19T10:38:10+01:00
- Author: Madison Wilson

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX), a commercial-stage biopharmaceutical
company, is gaining attention in the biotechnology sector, thanks to a robust analyst
consensus that forecasts a potential upside of 142.72%. With a current market capitalization
of $1.33 billion, Syndax is making significant strides in developing transformative
cancer therapies, which positions it as a compelling opportunity for investors seeking
growth in the healthcare sector.

The company’s flagship products, Revuforj (revumenib) and Niktimvo (axatilimab-csfr),
are at the forefront of its innovative pipeline. Revuforj, a menin inhibitor, is
being explored for the treatment of relapsed or refractory acute leukemia, while
Niktimvo is targeted at chronic graft-versus-host disease. Additionally, the development
of these therapies for conditions such as acute myeloid leukemia and metastatic 
colorectal cancer underscores Syndax’s commitment to addressing unmet medical needs.

From a valuation perspective, the company’s financial metrics reflect its developmental
stage. The absence of a trailing P/E ratio and the negative forward P/E of -9.30
highlight the company’s current focus on research and development over immediate
profitability. Despite these challenges, Syndax’s revenue growth rate of 984.50%
indicates significant progress, albeit with a net income and free cash flow currently
in the negative territory.

The company’s stock is presently trading at $15.45, with a 52-week range of $8.73
to $21.81, suggesting a volatile yet potentially rewarding investment. Notably, 
the technical indicators show a 50-day moving average of $13.26 and a 200-day moving
average of $12.81, indicating a positive short-term trend. However, with a Relative
Strength Index (RSI) of 47.05, the stock is neither overbought nor oversold, suggesting
a neutral investor sentiment at present.

Analysts remain bullish on Syndax, as evidenced by 13 buy ratings and no hold or
sell recommendations. The target price range of $19.00 to $56.00, with an average
target of $37.50, aligns with optimistic growth expectations. Such a consensus reflects
confidence in the company’s strategic direction and potential to deliver substantial
returns.

While the company does not currently offer a dividend, which might deter income-
seeking investors, its focus remains firmly on long-term capital appreciation through
groundbreaking biopharmaceutical advancements.

As Syndax Pharmaceuticals continues to advance its pipeline, investors are presented
with an opportunity to participate in potentially significant value creation. The
company’s strategic developments and analyst endorsements suggest that it could 
be a high-reward investment for those willing to embrace the inherent risks of the
biotechnology industry.

Share on: